It is worth stressing that the FDA has allowed the use of Veyonda as a first line treatment. That is highly unusual for experimental drugs. Normally you are restricted to testing your drug on end-stage patients who have failed other therapies. The clinicians must have wanted this because of the very poor response rate to doxorubicin, and that is the best they have.
Ann: Veyonda FDA Approved Trial to Commence, page-16
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
